MP72-11 OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR PLASMACYTOID UROTHELIAL CARCINOMA: DEFINING THE NEED FOR IMPROVED LOCAL CANCER CONTROL (2015)

You have accessJournal of UrologyBladder Cancer: Invasive V1 Apr 2015MP72-11 OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR PLASMACYTOID UROTHELIAL CARCINOMA: DEFINING THE NEED FOR IMPROVED LOCAL CANCER CONTROL Patrick Cockerill, John Cheville, Stephen Boorjian, Andrew Blackburne, Prabin Thapa, Robert Tarrell, and Igor Frank Patrick CockerillPatrick Cockerill More articles by this author , John ChevilleJohn Cheville More articles by this author , Stephen BoorjianStephen Boorjian More articles by this author , Andrew BlackburneAndrew Blackburne More articles by this author , Prabin ThapaPrabin Thapa More articles by this author , Robert TarrellRobert Tarrell More articles by this author , and Igor FrankIgor Frank More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2645AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We evaluated oncologic outcomes after radical cystectomy (RC) in patients with plasmacytoid urothelial carcinoma (UC), and compared survival to that in patients with pure UC of the bladder. METHODS We identified 35 patients with plasmacytoid UC and 857 with pure UC who were treated with RC between 1980 and 2007. All pathologic specimens were re-reviewed by a single GU pathologist. Patients were matched 1:2 by age, gender, ECOG performance status, pathological tumor stage and nodal status to patients with UC. Survival was estimated using the Kaplan-Meier method and compared with the log rank test. RESULTS Patients with plasmacytoid UC were more likely to have extravesical disease (¡ÝpT3) (86% versus 42%, p<0.0001) and positive margins (31% versus 2.1%, p<0.0001), than patients with pure UC. They were also more likely to experience a local recurrence (RR 2.7, p=0.0004), with a 46% 10-year recurrence free survival compared to 79% in patients with pure UC. Patients with plasmacytoid UC displayed a trend toward decreased 10-year overall (15% versus 30%, p=0.07) and cancer specific survival (28% versus 51%, p=0.05). When patients with plasmacytoid UC were matched to those with pure UC, there were no significant differences in 10-year overall, cancer specific, local or distant recurrence free survival. CONCLUSIONS Plasmacytoid UC is associated with a high rate of locally advanced disease and positive margins at RC, as well as increased local recurrence rates. Further research is necessary to delineate adjuvant or neoadjuvant treatment strategies to improve local cancer control this rare subtype of UC. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e924-e925 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Patrick Cockerill More articles by this author John Cheville More articles by this author Stephen Boorjian More articles by this author Andrew Blackburne More articles by this author Prabin Thapa More articles by this author Robert Tarrell More articles by this author Igor Frank More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...